SCHEMBL6600932

SCHEMBL6600932

O=C(O)CC(O)(CC(=O)Oc1ccccc1)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.52
SLC13A5 Q86YT5 9/20 0.47
KDM4E B2RXH2 6/20 0.44
LMNA P02545 5/20 0.44
MEN1 O00255 3/20 0.44
CYP1A2 P05177 3/20 0.44
CYP2D6 P10635 3/20 0.44
KMT2A Q03164 3/20 0.44
CYP19A1 P11511 1/20 0.42
MAPT P10636 3/20 0.41
TP53 P04637 2/20 0.41
CYP2C9 P11712 2/20 0.41
MAPK1 P28482 2/20 0.41
GMNN O75496 1/20 0.41
ESR1 P03372 1/20 0.41
CYP3A4 P08684 1/20 0.41
TSHR P16473 1/20 0.41
ALOX12 P18054 1/20 0.41
NFKB1 P19838 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28105443 0.98 ALDH1A1 (0.50) ALDH1A1SLC13A5KDM4ELMNAMEN1
Ammonia Solution, Strong SCHEMBL21219130 0.98 ALDH1A1 (0.50) ALDH1A1SLC13A5KDM4ELMNAMEN1
SCHEMBL27589888 0.98 ALDH1A1 (0.50) ALDH1A1SLC13A5KDM4ELMNAMEN1
Ammonia Solution, Strong SCHEMBL21219126 0.93 CYP19A1 (0.45) ALDH1A1SLC13A5KDM4ELMNAMEN1
SCHEMBL28299869 0.93 ALDH1A1 (0.56) ALDH1A1SLC13A5KDM4ELMNAMEN1
SCHEMBL28023748 0.91 SLC13A5 (0.56) ALDH1A1SLC13A5KDM4ELMNAMEN1
SCHEMBL2169485 0.87 ALDH1A1 (0.48) ALDH1A1SLC13A5KDM4ELMNAMEN1
SCHEMBL28159769 0.87 CYP19A1 (0.41) ALDH1A1SLC13A5KDM4ELMNAMEN1
SCHEMBL28861794 0.85 ALDH1A1 (0.47) ALDH1A1SLC13A5KDM4ELMNAMEN1
SCHEMBL28826320 0.85 ALDH1A1 (0.47) ALDH1A1SLC13A5KDM4ELMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116099537-A Ni-NiO multiphase magnetic catalyst, preparation method and application thereof 东南大学 2023-05-12 CN claimed
CN-101453993-A Controlled release delivery device containing organosol coating ISA ODIDI (CA) 2009-06-10 CN claimed
CN-1610664-A 3-azabicyclo [3.1.0] hexane derivatives as opioid receptor antagonists PFIZER PROD INC (US) 2005-04-27 CN claimed
CN-1071692-A Method for making lamp candle LIN GUOLONG (CN) 1993-05-05 CN claimed
US-20250312270-A1 READY-TO-INFUSE PHENYLEPHRINE COMPOSITIONS AMNEAL EU, LIMITED (IE) 2025-10-09 US disclosed
US-20250025409-A1 READY-TO-INFUSE PHENYLEPHRINE COMPOSITIONS AMNEAL EU, LIMITED (IE) 2025-01-23 US disclosed
US-20240351957-A1 ADMIXTURE TO CONTROL THE HEAT FLOW FROM MINERAL BINDER COMPOSITIONS, MINERAL BINDER COMPOSITIONS, AND PRODUCTION METHOD THEREOF SIKA TECHNOLOGY AG (CH) 2024-10-24 US disclosed
WO-2024175610-A1 METHODS FOR THE APPLICATION IN THICK LAYER OF CEMENTITIOUS COMPOSITIONS COMPRISING KINETIC REGULATOR SIKA TECHNOLOGY AG (CH) 2024-08-29 WO disclosed
WO-2024175602-A1 LIGHTWEIGHT CEMENTITIOUS COMPOSITION HAVING KINETIC REGULATOR SIKA TECHNOLOGY AG (CH) 2024-08-29 WO disclosed
EP-4417587-A1 METHODS FOR THE APPLICATION IN THICK LAYER OF CEMENTITIOUS COMPOSITIONS COMPRISING KINETIC REGULATOR Sika Technology AG (CH) 2024-08-21 EP disclosed
EP-4417588-A1 LIGHTWEIGHT CEMENTITIOUS COMPOSITION HAVING KINETIC REGULATOR Sika Technology AG (CH) 2024-08-21 EP disclosed
EP-4396150-A1 ADMIXTURE TO CONTROL THE HEAT FLOW FROM MINERAL BINDER COMPOSITIONS, MINERAL BINDER COMPOSITIONS, AND PRODUCTION METHOD THEREOF Sika Technology AG (CH) 2024-07-10 EP disclosed
EP-1440059-A1 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS Pfizer Products Inc. (US) 2004-07-28 EP disclosed
CN-1136219-C Pyrazolopyrimidinone derivatives for the treatment of impotence ������ҩ��ʽ���� 2004-01-28 CN disclosed
WO-2003035622-A1 3-AZABICYCLO (3.1.0) HEXANE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS PFIZER PRODUCTS INC. (US) 2003-05-01 WO disclosed
CN-1325398-A Pyrazolopyrimidinone derivatives for the treatment of impotence DONG A PHARM CO LTD (KR) 2001-12-05 CN disclosed
CN-1237901-A Protein-stabilized pharmacologically active agents and methods for their preparation and use VIVORX PHARMACEUTICALS INC (US) 1999-12-08 CN disclosed
CN-1138827-A Process for solubilizing difficultly soluble pharmaceutical actives PROCTER & GAMBLE (US) 1996-12-25 CN disclosed
CN-1071692-A Method for making lamp candle LIN GUOLONG (CN) 1993-05-05 CN disclosed
CN-1071692-A Method for making lamp candle LIN GUOLONG (CN) 1993-05-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250312270-A1 READY-TO-INFUSE PHENYLEPHRINE COMPOSITIONS REN, PEF1, AVPR2 ALDH1A1 1900/4885SLC13A5 57/4885KDM4E 3182/4885
US-20250025409-A1 READY-TO-INFUSE PHENYLEPHRINE COMPOSITIONS REN, PEF1, AVPR2 ALDH1A1 1900/4885SLC13A5 57/4885KDM4E 3182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.